



VIRTUAL CAREER PANEL SERIES

Careers in RNA therapeutics: *From bench to biotech*

Wednesday, May 6th, 2026

12:30 - 2:00 PM (EDT) / 9:30 -11:00 AM (PDT)

Topics to be covered include: *How to transition from academia to biotech, skills and training valuable in RNA therapeutics, expectations in the industry work environment*



Louis-Philippe Bernier, PhD

CEO and Co-Founder at *CereCura Nanotherapeutics*

At CereCura, a University of British Columbia spin-off developing RNA therapeutics for neurological diseases, Dr. Bernier, leads a multidisciplinary team focused on developing innovative LNP-mRNA therapies for CNS disorders— with preclinical programs in lysosomal storage disorders, Parkinson's and Alzheimer's Diseases, as well as regenerative medicine for spinal cord injury.



Loïc Vincent, PhD

Chief Scientific Officer at *Korro Bio*

Loïc brings over 20 years of experience in drug discovery & translational research across academia, biotech and the pharmaceutical industry, with deep expertise in oncology and immunology-related disorders. Throughout his career, Dr. Vincent led teams that advanced more than 20 drugs into clinical development based on various therapeutic modalities including small molecules, biologics, viral platforms, and cell therapies.



Soultan Al-Halifa, PhD

R&D director at *Feldan Therapeutics*

Soultan is a biotechnology leader specializing in intracellular delivery technologies for next-generation therapeutics, including RNA-based medicines. At Feldan Therapeutics, he leads a multidisciplinary team developing a proprietary peptide-based delivery platform designed to improve the intracellular delivery of biologics by enhancing cellular uptake and endosomal escape—key barriers that have historically limited the therapeutic potential of antisense oligonucleotides (ASOs).

Register for the event and become an **RNA Canada member!**